Financial Performance - The company's operating revenue for 2025 is approximately CNY 905.22 million, a slight decrease of 0.13% compared to the previous year[2] - Total profit for the period reached CNY 110.23 million, representing a significant increase of 93.07% year-on-year[2] - Net profit attributable to shareholders was CNY 86.07 million, up 88.76% from the previous year[2] - The basic earnings per share increased to CNY 0.4190, reflecting an 88.74% growth compared to the same period last year[2] Assets and Equity - Total assets at the end of the reporting period were CNY 754.67 million, a 9.64% increase from the beginning of the period[3] - Shareholder equity rose to CNY 617.30 million, marking an 11.96% increase from the start of the period[3] Business Expansion - The company successfully launched its largest egg product processing base in Southwest China, enhancing its supply chain capabilities[4] - The company is expanding its C-end business with new retail products, including small-packaged liquid eggs and welfare-certified eggs, which have gained consumer recognition[4] - The company is actively pursuing overseas market opportunities, resulting in significant growth in foreign income due to rising international egg prices[5] - The company's lysozyme project has been successfully launched and exported, creating new profit growth points[5]

证券代码：688691 证券简称：灿芯股份 公告编号：2026-003 灿芯半导体（上海）股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载灿芯半导体（上海）股份有限公司（以下简称"公司"） 2025 年度主要财务数据为初步核算数据，未经会计师事务所审计，具体 数据以公司 2025 年年度报告为准，提请投资者注意投资风险。 报告期内经营业绩变化的主要原因：1、受部分下游客户需求波动影 响，公司芯片量产业务收入下滑，导致公司营业收入下降；2、受项目情 况及收入结构等变化影响，公司毛利率同比下降；3、为进一步巩固公司 在芯片设计服务领域的技术优势，公司持续围绕"IP+平台"开展研发工 作，2025 年度研发费用同比增长。 报告期末，公司总资产为 164,326.77 万元，较期初减少 5.31%；归 属于母公司的所有者权益为 123,229.76 万元，较期初减少 9.75%。 | | | | 单位：万元 | | --- | --- | --- | --- | | 项目 | 本 ...

Financial Performance - Total operating revenue for 2025 reached RMB 1,129.67 million, a year-on-year increase of 2.16%[5] - Operating profit decreased to RMB 134.48 million, down 9.74% compared to the previous year[5] - Net profit attributable to shareholders of the parent company was RMB 111.09 million, a decline of 11.55% year-on-year[5] - Basic earnings per share decreased to RMB 0.2314, down 11.58% from the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 4,403.80 million, an increase of 3.61% from the beginning of the period[5] - The company's equity attributable to shareholders of the parent company rose to RMB 3,460.70 million, up 1.57% from the start of the period[5] Investment and Strategy - The company increased its investment in R&D, leading to a decrease in net profit primarily due to reduced cash management income[5] - The company is focusing on market expansion by consolidating traditional business advantages and exploring emerging fields[5] Financial Data Integrity - No financial data showed a change of 30% or more during the reporting period[6] - The financial data presented is preliminary and unaudited, with final figures to be disclosed in the 2025 annual report[7]

Financial Performance - The total operating revenue for 2025 reached RMB 230.72 million, a significant increase of 666.65% compared to RMB 30.09 million in the same period last year[3] - The net profit attributable to the parent company was a loss of RMB 536.22 million, which is a 32.74% reduction in losses compared to RMB 797.27 million in the previous year[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of RMB 579.22 million, narrowing losses by 27.99% from RMB 804.33 million year-on-year[3] - The basic earnings per share decreased by 32.26% to RMB -1.47 from RMB -2.17 in the previous year[3] - The company reported a weighted average return on net assets of -28.93%, an improvement of 3.72 percentage points from -32.65% in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were RMB 2,992.66 million, down 4.87% from RMB 3,145.72 million at the beginning of the period[3] - Equity attributable to the parent company decreased by 25.49% to RMB 1,584.20 million from RMB 2,126.04 million year-on-year[3] Revenue Growth Drivers - The company attributed the revenue growth to the market expansion of its first commercialized product, the Saliqi monoclonal antibody injection (Jinlixi®), which saw steady sales growth[6] - The significant increase in revenue was also supported by substantial licensing income from the GR1803 injection commercialization agreement[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final results to be disclosed in the 2025 annual report[4]

Financial Performance - The company reported total operating revenue of RMB 157.36 million for the reporting period, a decrease of 18.99% compared to the same period last year[5]. - The net profit attributable to the parent company was RMB -20.29 million, representing a decline of 152.40% year-on-year[5]. - The total assets at the end of the reporting period were RMB 830.76 million, down 3.40% from the beginning of the period[5]. - The equity attributable to the parent company decreased by 3.97% to RMB 779.13 million[5]. - Basic earnings per share fell to RMB -0.24, a decrease of 148.98% compared to the previous year[5]. - The weighted average return on net assets decreased by 8.06 percentage points to -2.55%[3]. - The financial data presented is preliminary and subject to final audit, with potential discrepancies in the annual report[9]. Investment and Expenses - The company increased its R&D investment to enhance product competitiveness, leading to higher R&D expenses during the reporting period[6]. - Sales expenses also increased as the company expanded and optimized its sales team to capture more market share[6]. Credit and Profitability - The company experienced a rise in credit impairment losses compared to the same period last year, impacting overall profitability[7].

Financial Performance - The total operating revenue for 2025 was RMB 211,669.47 million, an increase of 6.09% compared to the previous year[6] - The operating profit for 2025 was RMB -12,001.93 million, a decrease of 1,484.94% year-on-year[6] - The net profit attributable to shareholders of the parent company was RMB -11,953.13 million, down 1,577.02% from the previous year[6] - The basic earnings per share for 2025 was RMB -0.45, a decline of 1,600.00% compared to the previous year[6] Assets and Equity - The total assets at the end of the reporting period were RMB 322,927.83 million, a growth of 4.06% from the beginning of the period[8] - The equity attributable to shareholders of the parent company decreased by 5.88% to RMB 137,244.72 million[8] Strategic Plans and Investments - The company plans to achieve an operating revenue of RMB 2.117 billion in 2025, driven by innovation and IT product sales[8] - Increased R&D and marketing expenses were noted as the company invests in AI technology and new product market expansion[9] - The company emphasizes the need for time to scale new business products due to market conditions and customer decision cycles[8] Expenses - The company incurred a total of RMB 4,419.36 million in expenses related to employee stock options and convertible bond interest, impacting net profit[9]

Financial Performance - Total revenue for 2025 was approximately CNY 1,377.88 million, remaining stable compared to the previous year[3] - Net profit attributable to shareholders of the parent company was a loss of CNY 16.97 million, an improvement from a loss of CNY 18.09 million in the previous year[3] - The basic earnings per share improved slightly to -CNY 0.04 from -CNY 0.05 in the previous year[3] Assets and Equity - The company reported a decrease in total assets by 2.56% to CNY 4,919.59 million compared to the beginning of the period[5] - Shareholders' equity attributable to the parent company decreased by 3.79% to CNY 3,795.72 million[3] Operational Factors - The company experienced a significant reduction in operating losses, attributed to various operational factors[6] - Research and development expenses saw a slight decrease year-on-year, despite increased sales expenses due to market expansion efforts[5] - The company is actively expanding its innovative business and overseas markets, which contributed to increased sales expenses[5] Tax Impact - The VAT rate for biological products increased from 3% to 13%, negatively impacting overall revenue and profitability[5] Financial Reporting - Investors are advised to note that the financial data is preliminary and unaudited, with final results to be disclosed in the annual report[7]

一、2025 年度主要财务数据和指标 1 单位：人民币元 项目 本报告期 上年同期 增减变动幅度（％） 营业总收入 398,399,778.38 402,339,136.10 -0.98 营业利润 26,663,495.51 41,383,262.27 -35.57 利润总额 24,655,988.29 41,033,285.78 -39.91 归属于母公司所有者的净利润 23,418,088.41 36,803,794.65 -36.37 归属于母公司所有者的扣除非 经常性损益的净利润 14,940,257.48 35,875,603.46 -58.36 基本每股收益 0.37 0.59 -37.29 加权平均净资产收益率（%） 2.77 4.55 减少 1.78 个百分点 本报告期末 本报告期初 增减变动幅度（％） 总资产 931,798,089.41 1,032,804,511.08 -9.78 归属于母公司的所有者权益 820,392,562.99 812,137,037.81 1.02 股本 63,479,740.00 63,058,328.00 0.67 归属于母公司所有者的每股净 12.92 1 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥453,008,114.73, an increase of 11.14% compared to ¥407,606,791.47 in the same period last year[3] - Total profit for the reporting period was ¥68,547,018.24, reflecting a growth of 0.88% from ¥67,950,785.52 year-on-year[3] - Net profit attributable to shareholders was ¥60,335,342.11, up 1.32% from ¥59,551,444.06 in the previous year[3] Assets and Equity - The company's total assets at the end of the reporting period amounted to ¥830,869,170.86, a significant increase of 43.23% from ¥580,098,355.21 at the beginning of the period[3] - Shareholders' equity attributable to the company reached ¥645,510,081.74, marking a 58.66% increase from ¥406,844,936.50[3] Earnings and Returns - The company's basic earnings per share decreased by 12.12% to ¥0.87 from ¥0.99 in the previous year[3] - The weighted average return on net assets (after deducting non-recurring gains and losses) was 11.08%, down from 15.84% year-on-year[3] Capital Changes - The company issued new shares during the reporting period, resulting in a 38.33% increase in share capital to ¥83,000,000.00[6] - The capital reserve increased by 209.26% to ¥303,868,731.15, primarily due to the premium from the issuance of new shares[6] Foreign Exchange Impact - The company experienced increased foreign exchange losses due to the appreciation of the RMB, which impacted profit growth[5]

Financial Performance - The company's operating revenue for the reporting period was CNY 2,186,265,153.51, a decrease of 61.44% compared to the same period last year[4] - The total profit for the period was CNY 93,153,961.86, down 73.88% year-on-year[4] - The net profit attributable to shareholders was CNY 78,289,114.39, reflecting a 77.01% decline compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 21,141,752.12, a decrease of 92.03% year-on-year[4] - Basic earnings per share were CNY 0.33, down 77.40% from the previous year[4] Assets and Equity - Total assets at the end of the reporting period were CNY 8,734,209,799.72, a decrease of 1.61% compared to the beginning of the period[4] - Shareholders' equity attributable to the company was CNY 4,216,926,400.10, an increase of 0.78% year-on-year[4] Industry Context - The decline in performance was primarily due to ongoing supply-demand mismatches in the photovoltaic industry, leading to weak equipment demand from downstream companies[7] - The company has made necessary impairment provisions based on prudence, contributing to the overall decline in operating performance[7] Caution for Investors - Investors are advised to exercise caution as the reported data is preliminary and unaudited, with final figures to be disclosed in the annual report[8]